The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Thalassemia Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCAT 2023 | Pyruvate kinase activators for the treatment of thalassemia
Maria Domenica Cappellini, MD, University of Milan, Milan, Italy, discusses the possibility of using pyruvate kinase activators for the treatment of patients with thalassemia. These agents are used to treat pyruvate kinase deficiency, but recent trials provide evidence for their efficacy in the treatment of thalassemia. This interview was recorded at the 18th Annual Scientific Conference on Sickle Cell and Thalassemia (ASCAT) 2023, held in London, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
